Tralokinumab as an Alternative to Dupilumab in a Patient with Atopic Dermatitis and Asthma who Developed Hypereosinophilia: A Case Report

Ilaria Trave,Ilaria Salvi,Diego Bagnasco,Aurora Parodi,Emanuele Cozzani

DOI: https://doi.org/10.2340/actadv.v104.40800

2024-09-19

Abstract:Abstract is missing (Short communication)

dermatology

What problem does this paper attempt to address?

Efficacy of dupilumab in patient with hypereosinophilic syndrome and asthma non-responsive to anti-IL5 and anti-IL5r treatment.

Ochab-Krupnik,D.,Lacwik,P.,Moscicka,A.,Chrusciel,B.,Barwinek-Grajek,K.,Sleiman,Y.,Pałczynski,C.

DOI: https://doi.org/10.1183/13993003.congress-2024.pa4752

IF: 24.3

2024-11-01

European Respiratory Journal

Abstract:Background: Hypereosinophilic syndrome (HES) is a heterogeneous group of disorders characterized by persistent eosinophilia and associated organ damage. Comorbid asthma in HES patients poses a therapeutic challenge, especially in cases resistant to standard eosinophil-lowering therapies. This case report describes the effective management of a 31-year-old patient with HES and asthma using dupilumab after unsuccessful treatments with mepolizumab and benralizumab. Case Presentation: A 31-year-old individual with a lifelong history of severe asthma and HES, presented with uncontrolled symptoms and 4 yearly exacerbations despite previous treatment with high-dose inhaled corticosteroids and two different biologics over the last 5 years: initially with mepolizumab (300-700mg q4w), which was withdrawn after 3 years due to diminishing efficacy and benralizumab (30mg q4w), which was ceased after 6 months due to lack of response. The patient exhibited poor asthma control and recurrent exacerbations, despite low blood eosinophil levels. Following a comprehensive evaluation, treatment with dupilumab was initiated. Results: Remarkable improvement was observed within first 2 weeks of starting dupilumab. At a 6-month checkpoint we observed a significant improvement in both ACQ (from 3.5 to 0.9) and AQLQ (2.3 to 5.9) scores. The patient did not experience any exacerbations and managed to reduce daily dose of oral corticosteroids from 25mg to 10mg of prednisone. No significant adverse effects or increase in eosinophil counts were noted during the treatment course.

respiratory system
Eosinophilic pleural effusion and stroke with cutaneous vasculitis: Two cases of dupilumab‐induced hypereosinophilia

Marek Lommatzsch,Paul Stoll,Jörg Winkler,Daniel Zeise‐Wehry,Michael Tronnier,Marc‐André Weber,J. Christian Virchow

DOI: https://doi.org/10.1111/all.14964

IF: 12.4

2021-06-22

Allergy

Abstract:Allergy, Accepted Article.

immunology,allergy
Dupilumab-associated (hyper)eosinophilia in patients with atopic dermatitis: a single-center cohort study of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry

Angelo Li,Annelie H Musters,Ariënna Hyseni,Louise A A Gerbens,Phyllis I Spuls

DOI: https://doi.org/10.1093/bjd/ljae289

IF: 11.113

2024-07-15

British Journal of Dermatology

Abstract:This study investigated the incidence and progression of (hyper)eosinophilia in atopic dermatitis (AD) patients treated with dupilumab, using data from the TREAT NL registry cohort. In total, 38.5% of patients had (hyper)eosinophilia at baseline and/or during dupilumab treatment. (Hyper)eosinophilia was present at baseline in 43 (55.8%) patients and developed in 34 (44.2%) patients during treatment. Eosinophilia was transient, peaking at 6 months and normalizing by 18-24 months. One patient discontinued dupilumab due to persistent hypereosinophilia, but generally, eosinophilia did not affect treatment outcomes. In conclusion, dupilumab is found viable for AD patients regardless of baseline eosinophilia, with temporary increases in eosinophil counts that are often not clinically significant

dermatology
Dupilumab-induced eosinophilia in patients with diffuse type 2 chronic rhinosinusitis

Fabio S Ryser,Ayla Yalamanoglu,Alan Valaperti,Catrin Brühlmann,Tina Mauthe,Stephan Traidl,Michael B Soyka,Urs C Steiner

DOI: https://doi.org/10.1111/all.15844

IF: 12.4

Allergy

Abstract:Background: Dupilumab, a monoclonal anti-IL-4Rα antibody, is approved for several type 2 mediated inflammatory diseases like asthma, atopic dermatitis, and diffuse type 2 chronic rhinosinusitis (CRS). Clinical studies had reported a transient increase in blood eosinophils during dupilumab therapy. This study aimed to assess the impact of elevated blood eosinophils on clinical outcome and to investigate the cause of high blood eosinophil levels under dupilumab therapy. Methods: Patients suffering from diffuse type 2 CRS treated with dupilumab were examined on days 0, 28, 90, and 180 after therapy start. Sino-Nasal-Outcome-Test Score (SNOT-22), Total Nasal Polyp Score (TNPS), and blood samples were collected. Cytokine measurements and proteomics analysis were conducted. Flow cytometry analysis measured receptor expression on eosinophils. Results: Sixty-eighty patients were included. Baseline eosinophilia ≥0.3G/L was observed in 63.2% of patients, and in 30.9% of patients, eosinophils increased by ≥0.5G/L under dupilumab. Subjects with eosinophilia ≥0.3G/L at baseline had the best SNOT-22 mean change compared to no eosinophilia. Eosinophil elevation during dupilumab therapy had no impact on clinical scores. The eosinophil adhesion molecule VCAM-1 decreased significantly during therapy in all patients. The chemokine receptor CXCR4 was significantly down- and IL-4 upregulated in subjects with eosinophil increase. Conclusion: Our findings suggest that increased eosinophils in type 2 CRS are associated with a good clinical response to dupilumab. Patients with elevated IL-4 at baseline developed dupilumab-induced transient eosinophilia. We identified the downregulation of VCAM-1 and surface markers CD49d and CXCR4 on eosinophils as possible explanations of dupilumab-induced eosinophilia.
548 - Tralokinumab improves signs and symptoms of moderate-to-severe atopic dermatitis in patients aged 12 years and older with and without atopic comorbidities

Amy S Paller,Weily Soong,Mark Boguniewicz,Bob Geng,Jacob P Thyssen,Aldana Rosso,Louise Steffensen,Shannon Schneider,Andreas Wollenberg

DOI: https://doi.org/10.1093/bjd/ljad498.048

IF: 11.113

2024-02-01

British Journal of Dermatology

Abstract:Abstract Introduction/Background Atopic dermatitis (AD) is an inflammatory skin disease associated with atopic comorbidities, including asthma, food allergy, hay fever, and allergic conjunctivitis. Tralokinumab, a high-affinity monoclonal antibody that specifically targets IL-13, is indicated for the treatment of moderate-to-severe AD. Objectives To assess the impact of atopic comorbidities on the efficacy and safety of tralokinumab vs. placebo for moderate-to-severe AD in patients age ≥12 years. Methods This post-hoc analysis presents data from the adult trials ECZTRA 1 and 2 (NCT03131648 and NCT03160885 pooled; 300 mg tralokinumab every 2 weeks [Q2W] vs. placebo) and ECZTRA 3 (NCT03363854; 300 mg tralokinumab Q2W vs. placebo, both plus TCS as needed), and the ECZTRA 6 adolescent trial (NCT03526861; pooled 150 mg and 300 mg tralokinumab Q2W vs. placebo). Tralokinumab-treated patients received a loading dose. Proportion of patients achieving IGA 0/1 and EASI-75 at Week 16 according to patient-reported current or past atopic comorbidity are presented as observed regardless of rescue medication use; missing data were imputed as non-responders. Results In total 2,223 patients were included across four trials. Among patients in ECZTRA 1 and 2, 50.5% reported history of asthma, 38.5% food allergy, 53.8% hay fever, and 33.5% allergic conjunctivitis, while 19.8% reported no atopic comorbidities and 79.3% reported ≥1 atopic comorbidity. Proportions of patients in ECZTRA 3 and 6 reporting history of atopic comorbidities were largely similar, although more adolescent patients reported food allergy. In all subgroups at Week 16, higher proportions of patients receiving tralokinumab vs. placebo achieved EASI-75. In ECZTRA 1 and 2, response rates among patients in each subgroup were asthma: 35.3% vs. 12.8%, food allergy: 33.2% vs. 14.7%, hay fever: 36.8% vs. 16.5%, allergic conjunctivitis: 34.8% vs. 12.7%, none: 34.6% vs. 20.5%; and ≥1 atopic comorbidity: 35.5% vs. 15.2% (P<0.05 for all). A similar pattern of response was observed in ECZTRA 3 and 6, and for IGA 0/1 across trials. EASI-75 response rates for tralokinumab-treated patients were consistent across patients with different numbers of atopic comorbidities. Safety across subgroups was consistent with the safety profile of tralokinumab observed overall in adults and adolescents. Conclusions 16 weeks of tralokinumab treatment improved AD signs and symptoms in adult and adolescent patients with and without atopic comorbidities, regardless of type or number of atopic comorbidities. The safety profile of tralokinumab was consistent between patients with and without atopic comorbidities.

dermatology
Eosinophilia and Adverse Effects of Dupilumab for Respiratory Indications: A Real-World Setting

Sylvia H Li,Katharine Foster Nehme,Anna Moshkovich,Lydia Suh,Anna Pawlowski,Yasmeen Ali,Gayatri B Patel,Fei Li Kuang,Anju T Peters

DOI: https://doi.org/10.1016/j.jaip.2024.09.013

2024-09-23

Abstract:Background: Dupilumab has been used with significant benefit in the treatment of asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). Phase 3 clinical trials have demonstrated transient eosinophilia and rare eosinophil-related and other adverse effects. Objective: To characterize dupilumab-associated eosinophilia (absolute eosinophil count ≥1.5 × 103/μL within 36 weeks of dupilumab initiation) and adverse effects associated in real-world patients with asthma and CRSwNP in the United States. Methods: Retrospective chart review of 251 patients receiving dupilumab for asthma and/or CRSwNP seen at a single institution. Results: Among the 142 patients who had absolute eosinophil counts checked before and after treatment, 16 (11.3%) had posttreatment eosinophilia, including 11 (7.7%) who had new eosinophilia on dupilumab initiation. Thirteen patients with posttreatment eosinophilia remained on dupilumab, 10 of whom had resolution of eosinophilia. Eosinophil-related adverse effects were rare, and cases of eosinophilic granulomatous polyangiitis were limited to one patient with eosinophilia and one patient with normal eosinophil levels who was receiving systemic corticosteroids. Other adverse effects included arthralgias (13 of 251; 5.2%), rash (8 of 251; 3.2%), and conjunctivitis (7 of 251; 2.8%). All patients with pretreatment eosinophilia and most patients with posttreatment eosinophilia received significant treatment benefit for the respiratory disease with dupilumab. Conclusions: Whereas dupilumab-associated eosinophilia is seen in a subset of patients, persistent eosinophilia or eosinophil-related adverse effects are rare. Furthermore, treatment benefit with dupilumab despite eosinophilia supports its continued use in both asthma and CRSwNP.
549 - Laboratory parameters in adolescent patients aged 12–17 with moderate-to-severe atopic dermatitis treated with tralokinumab up to week 52: results from the phase 3 ECZTRA 6 trial

Amy Paller,Michael Cork,Chih-ho Hong,Weily Soong,Shannon Schneider,Hannah Lo,Line Rosendahl Meldgaard Pedersen,Emilia Vacko,Andreas Wollenberg

DOI: https://doi.org/10.1093/bjd/ljad498.049

IF: 11.113

2024-02-01

British Journal of Dermatology

Abstract:Abstract Introduction/Background Tralokinumab, a high-affinity, monoclonal antibody that targets IL-13, is approved in the EU and Canada for adolescents (aged ≥12 years) with inadequately controlled moderate-to-severe atopic dermatitis (AD), and it does not require laboratory monitoring. The phase 3 ECZTRA 6 (NCT03526861) clinical trial demonstrated efficacy and safety up to 52 weeks in that population. Objectives To further characterize the safety profile of tralokinumab by evaluating laboratory parameters of adolescents in the ECZTRA 6 trial. Methods ECZTRA 6 subjects received tralokinumab 150mg (n=98), 300mg (n=97) or placebo (n=94) every 2 weeks (Q2W) from week 0–16 after a loading dose at week 0 (twice the subsequent dose), and then randomized to maintenance [original tralokinumab dose either Q2W or every 4 weeks (Q4W) or placebo Q2W] or open-label (tralokinumab 300mg Q2W) until week 52. Laboratory parameters included hematology, serum biochemistry, and urinalysis throughout the trial (weeks 0, 8, 16, 28, and 52). Results Overall (n= 289 subjects), laboratory baseline parameters were similar across treatment groups. Mean and median changes of most hematology parameters showed minor fluctuations within the normal ranges through week 52, except for eosinophils. At baseline, elevated mean eosinophil counts (>0.5 109/L) were observed for 40.8% (tralokinumab 150mg), 48.5% (tralokinumab 300mg), and 43.6% (placebo) of subjects in each respective treatment group. Some tralokinumab-treated patients had small transient increases in eosinophils (maximum mean change from baseline 0.2×109/L) before week 16. Continued treatment with tralokinumab or placebo did not correspond with further increase in eosinophil levels over time, and no adverse events of eosinophilia were reported. Mean levels of most biochemistry parameters, including electrolytes, renal and liver function parameters, and lipid panel, were within normal range at baseline, and mean and median changes showed minor fluctuations within normal ranges in all treatment arms. Mean lactate dehydrogenase levels were around or above the upper limit of normal at baseline and decreased to within the normal ranges during the trial across all groups. Overall, no clinically meaningful differences were observed in hematology, biochemistry, or urinalysis parameters between active treatment groups or placebo. Conclusions Similar to findings in adult trials, no meaningful changes in laboratory parameters were observed in adolescents through week 52 with tralokinumab treatment. No routine laboratory monitoring is needed for adult or adolescent AD patients treated with tralokinumab.

dermatology
Safety of dupilumab in T2 airways conditions: focus on eosinophilia across trials and real-life evidence

Marco Caminati,Claudio Micheletto,Francesca Norelli,Bianca Olivieri,Giancarlo Ottaviano,Roberto Padoan,Giorgio Piacentini,Michele Schiappoli,Gianenrico Senna,Francesco Menzella

DOI: https://doi.org/10.1080/14712598.2024.2304556

2024-01-30

Expert Opinion on Biological Therapy

Abstract:Introduction Dupilumab, a monoclonal antibody targeting the IL-4 receptor alpha subunit, effectively blocks both IL-4 and IL-13 mediated pathways. Its introduction has represented a significant advancement in the treatment of severe asthma and other Type 2 (T2) conditions, including nasal polyps, atopic dermatitis, and eosinophilic esophagitis. To date, Dupilumab has demonstrated optimal efficacy and safety profile.

medicine, research & experimental,biotechnology & applied microbiology
Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*

A. Wollenberg,A. Blauvelt,E. Guttman‐Yassky,M. Worm,C. Lynde,J.‐P. Lacour,L. Spelman,N. Katoh,H. Saeki,Y. Poulin,A. Lesiak,L. Kircik,S.H. Cho,P. Herranz,M.J. Cork,K. Peris,L.A. Steffensen,B. Bang,A. Kuznetsova,T.N. Jensen,M.L. Østerdal,E.L. Simpson,the ECZTRA 1 and ECZTRA 2 study investigators,

DOI: https://doi.org/10.1111/bjd.19574

IF: 11.113

2020-12-30

British Journal of Dermatology

Abstract:BackgroundTralokinumab, a fully human monoclonal antibody, specifically neutralizes interleukin‐13, a key cytokine driving peripheral inflammation in atopic dermatitis (AD). In phase II studies, tralokinumab combined with topical corticosteroids provided early and sustained improvements in AD signs and symptoms. ObjectivesTo evaluate the efficacy and safety of tralokinumab monotherapy in adults with moderate‐to‐severe AD who had an inadequate response to topical treatments. MethodsIn two, 52‐week, randomized, double‐blind, placebo‐controlled, phase III trials, ECZTRA 1 and ECZTRA 2, adults with moderate‐to‐severe AD were randomized (3 : 1) to subcutaneous tralokinumab 300 mg every 2 weeks (Q2W), or placebo. Primary endpoints were IGA score of 0 or 1 at week 16 and EASI 75 at week 16. Patient achieving an IGA score of 0/1 and/or EASI 75 with tralokinumab at week 16 were rerandomized to tralokinumab Q2W or every 4 weeks or placebo, for 36 weeks. ResultsAt week 16, more patients who received tralokinumab vs. placebo achieved an IGA score of 0/1: 15·8% vs. 7·1% in ECZTRA 1 [difference (95% CI) 8·6% (4·1–13·1); P = 0·002] and 22·2% vs. 10·9% in ECZTRA 2 [11·1% (5·8–16·4); P < 0·001] and EASI 75: 25·0% vs. 12·7% [12·1% (6·5–17·7); P < 0·001] and 33·2% vs. 11·4% [21·6% (15·8–27·3); P < 0·001]. Early improvements in pruritus, sleep interference, Dermatology Life Quality Index, SCORing Atopic Dermatitis and Patient‐Oriented Eczema Measure were observed from the first postbaseline measurements. The majority of week 16 tralokinumab‐responders maintained response at week 52 with continued tralokinumab treatment without any rescue medication (including topical corticosteroids). Adverse events were reported in 76·4% and 61·5% of patients receiving tralokinumab and in 77·0% and 66·0% of patients receiving placebo in the 16‐week initial period. ConclusionsTralokinumab monotherapy was superior to placebo at 16 weeks of treatment and was well tolerated up to 52 weeks of treatment.

dermatology
Eosinophil Cationic Protein Variation in Patients with Asthma and CRSwNP Treated with Dupilumab

Andrea Giovanni Ledda,Giulia Costanzo,Giada Sambugaro,Cristiano Caruso,Martina Bullita,Maria Luisa Di Martino,Paolo Serra,Davide Firinu,Stefano Del Giacco

DOI: https://doi.org/10.3390/life13091884

2023-09-09

Life

Abstract:Background: Asthma is a clinical syndrome characterized by recurrent episodes of airway obstruction, bronchial hyperresponsiveness and airway inflammation. Most patients with asthma present a "type 2" (TH2) inflammation. ILC2 and TH2 cells release cytokines IL4, IL-13 and IL-5. CRSwNP is a condition characterized by hyposmia or anosmia, nasal congestion, nasal discharge, and face pain or pressure that last for at least 12 weeks in a row without relief. Both asthma and CRSwNP are often characterized by a type 2 inflammation endotype and are often present in the same patient. Dupilumab is a fully human monoclonal antibody targeting the interleukin-4 receptor α (IL-4Rα) subunit, blocking IL4/IL-4Rα binding and IL13. It has been labelled for the treatment of moderate to severe asthma in patients from the age of 12 years with an eosinophilic phenotype, and it has demonstrated efficacy and acceptable safety. Our study aims to investigate the effects of dupilumab on type 2 inflammatory biomarkers, such as eosinophils and eosinophil cationic protein (ECP). ECP is an eosinophil-derived substance contained in granules that are released during inflammation and causes various biological effects, including tissue damage in asthmatic airways. Methods: ECP, Eosinophil counts (EOS), and total immunoglobulin E (IgE) levels were longitudinally measured using immunoassays in the serum of 21 patients affected by CRSwNP, of which 17 had asthma as a comorbidity, receiving 300 mg dupilumab every two weeks. Results: The EOS and ECP, after a first phase of significant increase due to the intrinsic characteristic of the block of IL-4 and IL-13, returned to the baseline 10 months after the initial administration of dupilumab. Fractional exhaled nitric oxide (FeNO) and serum total IgE decreased significantly after 9 months. Asthma Control Test (ACT) scores improved after dupilumab treatment. FEV1% and FEV1 absolute registered a significant improvement at 10 months. Conclusions: Patients who received 300 milligrams of dupilumab every two weeks first experienced a temporary increase in eosinophils (EOS) and eosinophil cationic protein (ECP), then exhibited a gradual decline in these variables with a subsequent return to the initial baseline levels. When compared to the baseline, we observed that the levels of IgE and FeNO decreased over time, while there was an increase in both FEV1 and FEV1%.

biology
556 - A global, observational, cohort study of patients with atopic dermatitis to evaluate tralokinumab real-world clinical use (TRACE): baseline characteristics from the first 100 patients in Germany

Diamant Thaçi,Andreas Kleinheinz,Dimitra Maria Anastasiadou,John Stinson,April W Armstrong

DOI: https://doi.org/10.1093/bjd/ljad498.055

IF: 11.113

2024-02-01

British Journal of Dermatology

Abstract:Abstract Introduction/Background Tralokinumab is a high-affinity, fully human IgG4 monoclonal antibody that specifically targets interleukin-13, a key driver of atopic dermatitis (AD) disease progression. Clinical trials have shown that tralokinumab is efficacious in patients with moderate-to-severe AD and has a favorable safety profile, including a low frequency of adverse events such as conjunctivitis. Management of patients in routine clinical practice differs from those enrolled in clinical trials due to strict protocol criteria, and there is a lack of clinical data on tralokinumab use in the real-world setting. Objectives TRACE is a real-world study in patients with AD, aiming to better understand the effectiveness, safety, and clinical use of tralokinumab in daily practice. Here, we describe baseline characteristics from the first patients enrolled into TRACE in Germany. Methods TRACE is an observational, prospective, single-cohort study of adult patients with moderate-to-severe AD who are treated with tralokinumab, according to national approved labels. Eleven countries are participating in the study across Europe, North America and the Middle East. The primary objective is to assess changes in clinical signs and symptoms of AD in tralokinumab-treated patients. Secondary objectives are to investigate safety, quality of life, patient-reported outcomes and treatment adherence, among others. Results Of the first 100 patients initiated on tralokinumab, the mean age (standard deviation [SD]) was 44.7 years (17.9) and 58% were male. Most patients had moderate-to-severe AD with a mean Investigator’s Global Assessment (IGA) score of 3.5 (SD 0.7) and mean Eczema Area and Severity Index (EASI) of 22.5 (SD 12.9). Patients reported heavy symptomatic burden of disease; the mean eczema-related sleep numerical rating scale (NRS) was 5.6 (SD 2.9) and mean worst daily pruritus NRS was 6.2 (SD 2.7). Patients also reported a substantial impact on quality of life, demonstrated by a mean Dermatology Life Quality Index of 15.6 (SD 6.9). Overall, 79 patients were biologic-naïve and 19 were biologic-experienced (data missing; n=2). All biologic-experienced patients were previously treated with dupilumab, of whom most experienced one or more treatment failures. Reasons for switching from dupilumab included lack or loss of effectiveness, and adverse events, which most commonly included conjunctivitis. Conclusions Initial findings showed that most adult patients with moderate-to-severe AD who were treated with tralokinumab were biologic-naïve, indicating tralokinumab is prescribed as first-line systemic treatment in real-world clinical practice, in line with European Dermatology Forum guidelines. The main reasons for switching from dupilumab were lack or loss of effectiveness, and adverse events, such as conjunctivitis, indicating the need for alternative biologic treatments such as tralokinumab.

dermatology
Successful novel use of dupilumab for gastrointestinal involvement of idiopathic hypereosinophilic syndrome: case report and review of the literature

Clare Moffatt,Christopher Soriano,David W Dawson,Guy A Weiss

DOI: https://doi.org/10.1007/s12328-024-02036-4

2024-09-11

Abstract:Hypereosinophilic syndrome (HES) is characterized by blood and tissue hypereosinophilia leading to organ damage. Gastrointestinal involvement is the third most common manifestation. We present a patient with idiopathic HES with secondary eosinophilic esophagitis (EoE), gastritis, and enteritis, corticosteroids-dependent, azathioprine- and mepolizumab-refractory. The patient achieved clinical and histopathologic remission following dupilumab treatment. A 28 year-old female presented with chronic episodic nausea and emesis since childhood and initial diagnosis of primary eosinophilic gastrointestinal disease (EGID), improved with corticosteroids, refractory to azathioprine. She was found to have peripheral eosinophilia and multifactorial anemia, with iron, B12, and folate deficiencies. Esophageal, gastric, duodenal, and terminal ileum biopsies showed significant eosinophilic infiltrate. Bone marrow biopsy at age 31 confirmed HES diagnosis. By age 32, she became total parental nutrition (TPN)-dependent. She failed trials of benralizumab and mepolizumab [anti-interleukin (IL)-5 inhibitors], and cromolyn (mast-cell stabilizer). After developing new esophageal stricture, we initiated dupilumab (IL-4/13 inhibitor), recently FDA-approved for EoE. After 9 weeks, esophageal stricture, gut tissue eosinophilia, and prior intestinal ulcerations resolved. She ceased TPN and is tolerating a non-restricted diet, with complete symptom resolution. Our patient's complete remission with dupilumab shows promise for broadening its use in treating GI involvement in HES, along with primary EGIDs.
Asthma loss of control after switch from anti-IL5/5R drugs to dupilumab in severe eosinophilic asthma: a case series.

Poisson,C.,Chenivesse,C.,Cuvillon,E.,Barnig,C.,Clarot,C.,Dupin,C.,Mangiapan,G.,Rolland-Debord,C.,Bonniaud,P.,Taille,C.

DOI: https://doi.org/10.1183/13993003.congress-2024.pa5369

IF: 24.3

2024-11-01

European Respiratory Journal

Abstract:Background: In severe asthma (SA), severe respiratory and systemic complications have been described after switching from an anti-IL5 or IL5R to dupilumab, usually associated with blood hypereosinophilia (HE). Method: French multicenter retrospective study from 2021 to 2023 in patients treated with mepolizumab or benralizumab for severe hypereosinophilic asthma and who presented a worsening of asthma symptoms after switching to dupilumab. Results: 20 patients were analysed. The reason for the switch was insufficient control of asthma (A) in 16 or nasal polyposis (NP) in 4 patients. Asthma exacerbations (AE) described in all patients occurred within 6 months after the switch for 85% of the patients and were less severe in the NP group. AEs were always associated with HE, which was greater than 1000/mm3 in 16/20 cases. After the switch, a relapse of eosinophilic granulomatosis with polyangiitis (EGPA) with vasculitis lesions on nasal biopsy and a diagnosis of EGPA were made. In the A group, all patients received repeated or continuous oral corticosteroids (OCS). Dupilumab had to be stopped in 12/16 and continued in 4/16 patients alone or in combination with an anti-IL5/5R. Patients in the NP group did not require continuous OCS and dupilumab could be maintened in 3/4 patients. Conclusion: Switching from an anti-IL5/5R to dupilumab may represent a period at risk of severe AE associated with HE. The initiation of dupilumab after failure of an anti-IL5/IL5R must be monitored with particular attention regarding the unmasking/relapse of EGPA. The symptoms seem less severe when the switch is caused by nasal polyposis.

respiratory system
Effects of Tralokinumab on Clinical and Laboratory Indexes in Atopic Dermatitis: A 24-Week Real-World Study

Teppei Hagino,Marina Onda,Hidehisa Saeki,Eita Fujimoto,Naoko Kanda

DOI: https://doi.org/10.1089/derm.2024.0323

2024-10-03

Dermatitis

Abstract:Background: Tralokinumab, a monoclonal anti-IL-13 antibody, is approved for treating atopic dermatitis (AD). Real-world data on its effectiveness and safety are limited. Objective: To evaluate the real-world effectiveness and safety of tralokinumab and the transition of laboratory indexes during 24-week treatment for AD patients. Methods: This retrospective study included 104 patients with moderate-to-severe AD treated with tralokinumab 300 mg every 2 weeks after primary 600 mg. Clinical and laboratory indexes were assessed until week 24. Results: At week 24, achievement rates of Eczema Area and Severity Index 75 (EASI 75), EASI 90, and investigator's global assessment 0 out of 1 in systemic therapy-naïve patients, 83.3%, 72.2%, and 44.4%, respectively, were higher than those in systemic therapy-experienced patients, 46.7%, 20.0%, and 6.7%, respectively. Serum levels of immunoglobulin E (IgE), thymus and activation-regulated chemokine (TARC), and lactate dehydrogenase (LDH) significantly decreased at week 24, whereas neutrophil-to-lymphocyte ratio (NLR) and systemic inflammation response index (SIRI) significantly decreased at week 12 from baseline. Twenty-nine patients (27.9%) experienced mild treatment-emergent adverse events. Conclusions: Tralokinumab treatment showed prosperous therapeutic effects and good tolerability in real-world practice for AD, with higher effectiveness in patients without prior systemic therapy compared with those with prior systemic therapy. Tralokinumab treatment significantly decreased clinical and laboratory indexes, EASI, Peak Pruritus-Numerical Rating Scale, IgE, TARC, LDH, NLR, and SIRI.
Dupilumab treatment ameliorates clinical and hematological symptoms, including blood eosinophilia, in patients with atopic dermatitis

Teruo Yamauchi,Shun Sasaki,Eun Seon Lee,Takayuki Tamura,Marina Seki,Tasuku Miwa,Kae Kobayashi,Yusuke Saruta,Yuki Kitami,Hirohiko Sueki,Hideaki Watanabe

DOI: https://doi.org/10.1111/ijd.15183

2020-09-29

International Journal of Dermatology

Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>Atopic dermatitis (AD) is an allergic disease that affects individuals of various ages. Recently, the IL‐4/13 inhibitor dupilumab has gained regulatory approval for clinical use in AD patients. Dupilumab has been reported to reduce several markers of AD, including the serum levels of thymus and activation‐regulated chemokine (TARC/CCL17), blood lactate dehydrogenase (LDH), and serum total immunoglobulin E (IgE).</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>We retrospectively reviewed data from 40 AD patients who were treated with dupilumab. Eczema Area and Severity Index (EASI), Investigator's Global Assessment (IGA), body surface area (BSA) scores, TARC, LDH, total IgE, and eosinophil count in peripheral blood were assessed for a total of 32 weeks.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>The EASI, IGA, and BSA scores improved significantly with treatment, indicating a reduction in AD severity. Serum TARC and LDH levels also significantly decreased with treatment. Serum IgE levels were unchanged at 2 weeks of treatment but decreased significantly between 4 and 32 weeks. The number of eosinophils in the peripheral blood decreased at 4, 16, and 32 weeks after treatment initiation.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>Several studies have reported that serum TARC, LDH, and total IgE levels are reduced by dupilumab treatment. Our real‐world data are the first to demonstrate a reduction in blood eosinophilia in patients who receive clinical treatment with dupilumab.</p></section>

dermatology
Dupilumab for relapsing or refractory sinonasal and/or asthma manifestations in eosinophilic granulomatosis with polyangiitis: a European retrospective study

Berengere Molina,Roberto Padoan,Maria Letizia Urban,Pavel Novikov,Marco Caminati,Camille Taillé,Antoine Néel,Laurence Bouillet,Paolo Fraticelli,Nicolas Schleinitz,Christine Christides,Laura Moi,Bertrand Godeau,Ann Knight,Jan Walter Schroeder,Sylvain Marchand-Adam,Helder Gil,Vincent Cottin,Cécile-Audrey Durel,Elena Gelain,Boris Lerais,Marc Ruivard,Matthieu Groh,Maxime Samson,Luca Moroni,Jens Thiel,Anna Kernder,Jan Willem Cohen Tervaert,Giulia Costanzo,Marco Folci,Sonia Rizzello,Pascal Cohen,Giacomo Emmi,Benjamin Terrier

DOI: https://doi.org/10.1136/ard-2023-224756

Abstract:Background: Eosinophilic granulomatosis with polyangiitis (EGPA) is often associated with glucocorticoid-dependent asthma and/or ear, nose and throat (ENT) manifestations. When immunosuppressants and/or mepolizumab are ineffective, dupilumab could be an option. We describe the safety and efficacy of off-label use of dupilumab in relapsing and/or refractory EGPA. Patients and methods: We conducted an observational multicentre study of EGPA patients treated with dupilumab. Complete response was defined by Birmingham Vasculitis Activity Score (BVAS)=0 and prednisone dose ≤4 mg/day, and partial response by BVAS=0 and prednisone dose >4 mg/day. Eosinophilia was defined as an eosinophil count >500/mm3. Results: Fifty-one patients were included. The primary indication for dupilumab was disabling ENT symptoms in 92%. After a median follow-up of 13.1 months, 18 patients (35%) reported adverse events (AEs), including two serious AEs. Eosinophilia was reported in 34 patients (67%), with a peak of 2195/mm3 (IQR 1268-4501) occurring at 13 weeks (IQR 4-36) and was associated with relapse in 41%. Twenty-one patients (41%) achieved a complete response and 12 (24%) a partial response. Sixteen (31%) patients experienced an EGPA relapse while on dupilumab, which was associated with blood eosinophilia in 14/16 (88%) patients. The median eosinophil count at the start of dupilumab was significantly lower in relapsers than in non-relapsers, as was the median time between stopping anti-IL-5/IL-5R and switching to dupilumab. Conclusion: These results suggest that dupilumab may be effective in treating patients with EGPA-related ENT manifestations. However, EGPA flares occurred in one-third of patients and were preceded by eosinophilia in 88%, suggesting that caution is required.
Global influence of dupilumab on Quality of Life in a severe asthma patient with T2 multimorbidities: a case report on atopic dermatitis, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis

Monica Colque-Bayona,Natalia Hernández-Cano,Margarita Tomás-Pérez,Teresa Caballero,Santiago Quirce,Javier Domínguez-Ortega

DOI: https://doi.org/10.1080/02770903.2023.2300712

2024-01-05

Journal of Asthma

Abstract:Introduction Interleukin (IL)-4 and IL-13 are considered key drivers of type 2 inflammatory diseases. Dupilumab is a fully human monoclonal antibody that blocks the shared receptor component for IL-4 and IL-13, thus inhibiting signaling of both cytokines.

allergy,respiratory system
Switching of biological therapy to dupilumab in comorbid patients with severe asthma and CRSwNP

Cecilia Rosso,Eugenio De Corso,Valerio Conti,Letizia Nitro,Alberto Maria Saibene,Elena Parazzini,Rocco Rinaldo,Sabrina De Pascalis,Flavio Arnone,Stefano Centanni,Claudio Montuori,Leandro Maria D’Auria,Giovanni Felisati,Carlotta Pipolo

DOI: https://doi.org/10.1007/s00405-024-08461-y

2024-02-12

European Archives of Oto-Rhino-Laryngology

Abstract:Abstract Purpose Nowadays, several efficacious biologic drugs are used for severe asthma with or without chronic rhinosinusitis with nasal polyps (CRSwNP). However, it has been observed that not all comorbid patients (asthma/CRSwNP) receiving biologic treatment for asthma experience satisfactory control of both conditions equally. Methods We selected 20 patients who had both severe asthma and comorbid CRSwNP under biological treatment with benralizumab, omalizumab or mepolizumab with adequate control of asthma but inadequate control of nasal symptoms. Patients were switched to dupilumab and outcomes were evaluated at baseline (T0), at 3 months (T1), at 6 months (T2), at 12 months (T3) and finally at 18 months (T4). Data were collected at each time point including blood tests measuring eosinophil levels and total IgE, SNOT22, ACT, NPS score, rhinomanometry, olfactory testing, and nasal cytology. Results The results showed an overall improvement in all the outcomes. Peripheral eosinophilia was observed consistently with existing literature. All patients registered an improvement in sinonasal outcomes, while only one patient had a worsening of asthma. Three patients interrupted the therapy due to various causes: poor asthma control, onset of psoriasis and thrombocytopenia. Conclusions The response to a biologic treatment for CRSwNP control may be heterogenous and it seems that patients may benefit from switching improving control in equal measure in the upper and lower airway. Further studies to explore the endotype/phenotype which best fits with each biologic are mandatory to personalize the therapy.

otorhinolaryngology
553 - Tralokinumab real-world patient-reported outcomes in moderate-to-severe atopic dermatitis adult patients in the United States: 6-month interim analysis

Peter Lio,Yestle Kim,Sanjeev Balu,Halley Costantino,Dawn Bates,Cassandra Rene,Amanda Lopez,Jennifer Soung

DOI: https://doi.org/10.1093/bjd/ljad498.052

IF: 11.113

2024-02-01

British Journal of Dermatology

Abstract:Abstract Introduction/Background Tralokinumab, an IL-13 targeted biologic approved in the United States (US) for adult patients with moderate-to-severe atopic dermatitis (AD), improved patient-reported outcomes (PROs) in clinical trials and after 4 weeks of use in the real-world setting. Objectives This 6-month interim analysis evaluated the real-world impact of tralokinumab on PROs in adult patients. Methods This is an interim analysis of an ongoing 52-week patient survey study enrolling US AD patients from the AdbryTM AdvocateTM Program. Patients completed the baseline survey close to tralokinumab initiation. Data on demographics and PROs including weekly itch numeric rating scale (NRS), eczema-related weekly sleep NRS, Dermatology Life Quality Index (DLQI), and Treatment Satisfaction Questionnaire for Medication (TSQM-9) were collected. Percent and absolute changes from baseline to 6 months of treatment were calculated. Outcomes are stratified by previous dupilumab use. The percentage of patients experiencing minimal clinically important difference (MCID) was also calculated for itch NRS (3-point reduction) and DLQI (4-point reduction). Results As of May 2023, 102 patients completed baseline, 1-month, and 6-month surveys. Of these, 59.8% were female, mean age was 44.2 years (SD=15.7), 82.4% were white, and 85.3% had private insurance. 84.3% were previously treated with topical corticosteroids (TCS) and 52.9% were dupilumab-experienced patients. Over 6 months, there was an improvement in the mean sleep interference NRS (40%), average weekly itch NRS (39%), worst weekly itch NRS (33%), PO-SCORAD (37%), and DLQI (52%). There were improvements in mean TSQM-9 global satisfaction (11.06 points), TSQM-9 convenience (3.92 points), and TSQM-9 effectiveness (14.60 points) scores. Median MCIDs were met by 57.1% on the sleep interference NRS, 51.7% of patients on the average weekly itch NRS, 50.0% on the worst weekly itch NRS, and 68.7% on the DLQI. Relative to the dupilumab-experienced cohort, the dupilumab-naïve patients showed markedly improved outcomes [median MCIDs of 65.6% v 48.4% on sleep NRS; 59.5% v 44.4% on average weekly itch NRS; 61.4% v 39.6% on worst weekly itch NRS; 61.4% v 35.3% on PO-SCORAD; and 75.6% v 61.9% on DLQI]. Conclusions This 6-month interim analysis shows that tralokinumab improved quality of life outcomes related to itch, sleep, and treatment satisfaction when used either in dupilumab-naïve or in dupilumab-experienced patients. These patients will continue to be followed for up to 52 weeks of treatment with tralokinumab.

dermatology
Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age

Mirna Chehade,Evan S. Dellon,Jonathan M. Spergel,Margaret H. Collins,Marc E. Rothenberg,Robert D. Pesek,Ikuo Hirano,Ruiqi Liu,Elizabeth Laws,Eric Mortensen,Renata Martincova,Arsalan Shabbir,Eilish McCann,Mohamed A. Kamal,Matthew P. Kosloski,Jennifer D. Hamilton,Carin Samuely,Wei Keat Lim,Matthew F. Wipperman,Annamaria Farrell,Naimish Patel,George D. Yancopoulos,Lila Glotfelty,Jennifer Maloney

DOI: https://doi.org/10.1056/nejmoa2312282

IF: 158.5

2024-06-27

New England Journal of Medicine

Abstract:New England Journal of Medicine, Volume 390, Issue 24, Page 2239-2251, June 27, 2024.

medicine, general & internal

Tralokinumab as an Alternative to Dupilumab in a Patient with Atopic Dermatitis and Asthma who Developed Hypereosinophilia: A Case Report

Efficacy of dupilumab in patient with hypereosinophilic syndrome and asthma non-responsive to anti-IL5 and anti-IL5r treatment.

Eosinophilic pleural effusion and stroke with cutaneous vasculitis: Two cases of dupilumab‐induced hypereosinophilia

Dupilumab-associated (hyper)eosinophilia in patients with atopic dermatitis: a single-center cohort study of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry

Dupilumab-induced eosinophilia in patients with diffuse type 2 chronic rhinosinusitis

548 - Tralokinumab improves signs and symptoms of moderate-to-severe atopic dermatitis in patients aged 12 years and older with and without atopic comorbidities

Eosinophilia and Adverse Effects of Dupilumab for Respiratory Indications: A Real-World Setting

549 - Laboratory parameters in adolescent patients aged 12–17 with moderate-to-severe atopic dermatitis treated with tralokinumab up to week 52: results from the phase 3 ECZTRA 6 trial

Safety of dupilumab in T2 airways conditions: focus on eosinophilia across trials and real-life evidence

Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*

Eosinophil Cationic Protein Variation in Patients with Asthma and CRSwNP Treated with Dupilumab

556 - A global, observational, cohort study of patients with atopic dermatitis to evaluate tralokinumab real-world clinical use (TRACE): baseline characteristics from the first 100 patients in Germany

Successful novel use of dupilumab for gastrointestinal involvement of idiopathic hypereosinophilic syndrome: case report and review of the literature

Asthma loss of control after switch from anti-IL5/5R drugs to dupilumab in severe eosinophilic asthma: a case series.

Effects of Tralokinumab on Clinical and Laboratory Indexes in Atopic Dermatitis: A 24-Week Real-World Study

Dupilumab treatment ameliorates clinical and hematological symptoms, including blood eosinophilia, in patients with atopic dermatitis

Dupilumab for relapsing or refractory sinonasal and/or asthma manifestations in eosinophilic granulomatosis with polyangiitis: a European retrospective study

Global influence of dupilumab on Quality of Life in a severe asthma patient with T2 multimorbidities: a case report on atopic dermatitis, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis

Switching of biological therapy to dupilumab in comorbid patients with severe asthma and CRSwNP

553 - Tralokinumab real-world patient-reported outcomes in moderate-to-severe atopic dermatitis adult patients in the United States: 6-month interim analysis

Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age